...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Apabetalone treatment reduces SARS-CoV-2 infectivity and completely prevents cardiac damage in a cytokine-storm model

For the less knowledgeable regarding the science:

 

What is the liklihood of Apapbetalone having such a benefit on other disseases?

 

What is the cytokine storm issue’s prevalence amongst viral infections and diseases?

 

I have been reluctant to be excited about the Covid information because of the recent data suggesting rapid progression toward “herd immunity” and the increasing availability of the Moderna, Pfizer, JJ’s entries, etc.  However, if this is a groundbreaking development across many viral infections (infections in general?) that may reduce bad outcomes for things like the common cold and flu in the elderly…that’s big business.

 

So big that even this group of business visionaries may not be able to resist the temptation to capitalize on it.

 

It would be a dumb luck discovery on par with the little blue pill’s windfall.

Share
New Message
Please login to post a reply